SCHEMBL1519961

SCHEMBL1519961

CC(C)(C)OC(=O)C(CC(=O)O)Cc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.47
▸ FDFT1 P37268 1/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ CPA1 P15085 2/20 0.44
▸ CPB1 P15086 1/20 0.44
▸ CPA3 P15088 1/20 0.44
▸ CPB2 Q96IY4 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ PMP22 Q01453 1/20 0.44
▸ NLRP3 Q96P20 1/20 0.44
▸ PPARG P37231 1/20 0.42
▸ PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1519959 1.00 KMT2A (0.52) KMT2AMEN1L3MBTL1ALDH1A1FDFT1
SCHEMBL1916688 0.87 CPA1 (0.60) CYP1A2CPA1CPB1CPA3CPB2
SCHEMBL1519838 0.87 CPA1 (0.60) CYP1A2CPA1CPB1CPA3CPB2
SCHEMBL1519833 0.87 CPA1 (0.60) CYP1A2CPA1CPB1CPA3CPB2
SCHEMBL27745166 0.87 CYP3A4 (0.41) KMT2AMEN1L3MBTL1ALDH1A1CYP3A4
SCHEMBL19377834 0.86 MMP2 (0.48) CPA1CPB1CPA3CPB2PPARG
SCHEMBL19377835 0.86 MMP2 (0.48) CPA1CPB1CPA3CPB2PPARG
SCHEMBL3664929 0.84 KMT2A (0.59) KMT2AMEN1L3MBTL1ALDH1A1FDFT1
SCHEMBL1519592 0.83 PPARG (0.46) CPA1CPB1CPA3CPB2PPARG
SCHEMBL1519595 0.83 PPARG (0.46) CPA1CPB1CPA3CPB2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897619-B2 Heterocyclic modulators of PKB AMGEN INC. (US) 2011-03-01 — — US disclosed
EP-2173728-A2 HETEROCYCLIC MODULATORS OF PKB Amgen Inc. (US) 2010-04-14 — — EP disclosed
US-20090275592-A1 Heterocyclic modulators of PKB AMGEN INC. (US) 2009-11-05 — — US disclosed
WO-2009011880-A2 HETEROCYCLIC MODULATORS OF PKB AMGEN INC. (US) 2009-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275592-A1 Heterocyclic modulators of PKB MTOR, PDK1, EIF4EBP1 KMT2A 3140/4885MEN1 1764/4885L3MBTL1 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback